全文获取类型
收费全文 | 356篇 |
免费 | 20篇 |
国内免费 | 66篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 41篇 |
妇产科学 | 1篇 |
基础医学 | 32篇 |
口腔科学 | 25篇 |
临床医学 | 58篇 |
内科学 | 78篇 |
皮肤病学 | 1篇 |
神经病学 | 25篇 |
特种医学 | 96篇 |
外科学 | 14篇 |
综合类 | 17篇 |
预防医学 | 5篇 |
药学 | 35篇 |
中国医学 | 2篇 |
肿瘤学 | 10篇 |
出版年
2022年 | 1篇 |
2019年 | 3篇 |
2018年 | 2篇 |
2017年 | 3篇 |
2016年 | 4篇 |
2015年 | 2篇 |
2014年 | 3篇 |
2013年 | 5篇 |
2012年 | 6篇 |
2011年 | 6篇 |
2010年 | 7篇 |
2009年 | 10篇 |
2008年 | 10篇 |
2007年 | 35篇 |
2006年 | 10篇 |
2005年 | 9篇 |
2004年 | 3篇 |
2003年 | 6篇 |
2002年 | 14篇 |
2001年 | 15篇 |
2000年 | 12篇 |
1999年 | 11篇 |
1998年 | 28篇 |
1997年 | 26篇 |
1996年 | 25篇 |
1995年 | 18篇 |
1994年 | 18篇 |
1993年 | 10篇 |
1992年 | 1篇 |
1991年 | 3篇 |
1990年 | 11篇 |
1989年 | 15篇 |
1988年 | 16篇 |
1987年 | 12篇 |
1986年 | 11篇 |
1985年 | 16篇 |
1984年 | 4篇 |
1983年 | 7篇 |
1982年 | 8篇 |
1981年 | 8篇 |
1980年 | 5篇 |
1978年 | 7篇 |
1977年 | 4篇 |
1976年 | 5篇 |
1975年 | 7篇 |
排序方式: 共有442条查询结果,搜索用时 15 毫秒
1.
2.
Background
Management of high-grade T1 (formerly T1G3) bladder cancer continues to be controversial. Should patients with T1G3 bladder cancer have an immediate radical cystectomy or should they receive intravesical bacillus Calmette-Guérin preserving bladder? Gemcitabine and cisplatin (GC) adjuvant chemotherapy may help to strike a balance between intravesical and early cystectomy. For purposes of this study, we continue to refer high-grade T1 lesion as “T1G3.”Objective
To evaluate the characteristics and the long-term outcome of GC adjuvant chemotherapy in T1G3 bladder cancer after transurethral resection of bladder tumor (TURBT).Materials and methods
We, retrospectively, reviewed 48 patients who were newly diagnosed with T1G3 bladder cancer between January 2009 and December 2012. A total of 48 patients received 4 cycles of GC adjuvant chemotherapy after TURBT. One month after 4 cycles of GC adjuvant chemotherapy, response was evaluated by re-TURBT. Median follow-up was 59.5 (range: 18–70) months, all patients have been observed for more than 3 years. Salvage cystectomy was recommended for patients with persistent disease and for tumor progression after initial complete response.Result
Complete response was achieved in 44 (91.7%) patients. Of complete responders, 5 patients experienced recurrence and 5 patients showed progression. The progression rate and disease-specific survival rate were 10.4% and 91.7% at 3 years, respectively. More than 80% of survivors preserved their bladder. Kaplan-Meier curves showed that concomitant carcinoma in situ (CIS) was the only factor that had an influence on progression-free survival (P = 0.022) and disease-specific survival (P = 0.017). Concomitant CIS was the prognostic factor for progression rate and disease-specific survival rate at 3 years (P = 0.008 and P = 0.035).Conclusion
GC adjuvant chemotherapy is a safe conservative treatment for T1G3 bladder cancer, but effective is really a phase II study. Patients with T1G3 bladder cancer with concomitant CIS should be treated more aggressively because of the high risk of progression. 相似文献3.
4.
5.
M Altieri R Di Giambattista L Di Clemente D Fagiolo E Tarolla A Mercurio E Vicenzini L Tarsitani GL Lenzi M Biondi & V Di Piero 《Cephalalgia : an international journal of headache》2009,29(3):293-299
We studied the effects of short-term psychodynamic psychotherapy (STPP) and pharmacological therapy in 26 consecutive patients with probable medication overuse headache (pMOH). Patients underwent a standard in-patient detoxification protocol, lasting a mean of 7 days. Eleven patients overused non-steroidal anti-inflammatory drugs (NSAIDs), five a combination of NSAIDs and triptans, four triptans, four a combination of NSAIDs, and three triptans and ergot derivates. Preventive therapy was initiated during detoxification. The STPP protocol comprised the Brief Psychodynamic Investigation (BPI) and psychoanalysis-inspired psychotherapy. All patients (groups A and B) underwent the BPI and pharmacological therapy. Half of the patients (group B) also not randomly underwent psychoanalysis-inspired psychotherapy. We found a significant interaction between time and group for headache frequency and medication intake. At 12-month follow-up, a statistically greater decrease in headache frequency and medication intake was observed in group B than in group A ( P = 0.0108 and P = 0.0097, respectively). The relapse rate was much lower in group B patients at both 6 and 12 months [15.3%, odds ratio (OR) 0.11, P = 0.016, and 23%, OR 0.18, P = 0.047, respectively] than in group A. The risk of developing chronic migraine (CM) during follow-up was higher in group A than in group B at 6 (OR 2.0, P = 0.047) and 12 months (OR 2.75, P = 0.005). Our study suggests that STPP in conjunction with drug withdrawal and prophylactic pharmacotherapy relieves headache symptoms in pMOH, reducing both long-term relapses and the burden of CM. 相似文献
6.
7.
AIM:The present study was undertaken to isolate and standardize the various active phytochemical constituents present in the fruit rinds of Punica granatum.METHODS:Fruit rinds of Punica granatum were dried and extracted with methanol in a static extractor;the percentage yield of the methanolic extract (MEPG) was found to be 26%;the methanolic extract was partitioned using n-butanol,ethyl acetate and water;the percentage yield of the fractions were found to be 17.16%,26.88% and 47.72% respectively.HPLC was c... 相似文献
8.
9.
Vogel GL 《国际口腔医学杂志》2001,28(3):193
氟化钠(NaF)和单氟磷酸钠(NaMFP)是目前市售最常见的含氟牙粉。以前一致认为氟的抗龋效能取决于牙所处液体环境中Fˉ浓度,但其临床抗龋效果却与二者的Fˉ浓度出现较大差异。本研究定量分析NaF和NaMFP液漱口后,唾液、全菌斑及菌斑液中Fˉ、MFPˉ浓度的变化,揭示其不同的抗龋特性。 标本取自12位自愿受试者。每个象限各选一颗磨牙或前磨牙取菌斑。测前48h不刷牙,当晚禁食,次日上午收集龈下菌斑和唾液标本作为基线水 相似文献
10.
CARSTEN W. ISRAEL M.D. BURKHARD HÜGL M.D. CHRISTINA UNTERBERG M.D. THOMAS LAWO M.D. INGRID KENNIS DOUGLAS HETTRICK STEFAN H. HOHNLOSER M.D. 《Journal of cardiovascular electrophysiology》2001,12(10):1121-1128
INTRODUCTION: Patients with bradycardia requiring permanent pacing frequently suffer from additional atrial tachyarrhythmias (ATs). This study evaluated the safety and efficacy of atrial antitachycardia pacing (ATP) and the performance of pacing for AT prevention implemented into a new pacemaker. METHODS AND RESULTS: In patients with conventional indications for permanent pacing, an investigational DDDRP pacemaker (Medtronic AT500, model 7253) was implanted. The primary study objectives were to determine the safety of overall device functioning and its efficacy in terminating spontaneous AT. A secondary endpoint was to determine the reliability of AT detection. Pacemaker memory functions were used to analyze the impact of dedicated pacing algorithms on AT prevention. In 33 European and Canadian centers, 325 patients were enrolled (mean follow-up 2.3+/-1.3 months). Complication-free survival at 3 months was 88%. In 2,145 episodes stored with atrial electrograms, AT detection was confirmed in 97%. The algorithm for continuous overdrive pacing increased the percentage of atrial pacing to 97%. After ATP activation, 16,683 of 52,468 AT episodes were treated (120 patients). Of these, 8,903 episodes (53%) were terminated successfully by ATP. No proarrhythmic effect of preventive pacing or atrial ATP was observed. Preventive pacing algorithms increased the median percentage of atrial pacing from 62% to 97%. However, the number of AT/AF (atrial fibrillation) episodes (4.1 vs 4.1 per patient per day) and the time in AT/AF (13.7% vs 12.8%) was not significantly different before and after activation of preventive pacing. CONCLUSION: DDDRP pacing with a new system for AT therapy was safe and associated with successful pace-termination of AT in 53% of episodes. Preventive pacing and atrial ATP algorithms represent two new functions that can be implemented safely into pacemaker systems for nonpharmacologic treatment of ATs in patients requiring pacemaker therapy. 相似文献